The EPS projection of Diplomat Pharmacy, Inc. (NYSE:DPLO) for quarter ended 2016-09-30 is $0.24. A week before, the EPS forecast was $0.24 against target of $0.24, a month earlier. This estimate stood at $0.24 60 days earlier versus forecast of $0.24 90 days earlier, confirming a deviation of 0%.
Diplomat Pharmacy, Inc. (NYSE:DPLO) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 3.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 3, 0 and 3, respectively.
The downgrade of EPS estimates for Diplomat Pharmacy, Inc. (NYSE:DPLO) in the preceding 120, 60, 30 and 90 days were 4, 2, 0 and 2, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Diplomat Pharmacy, Inc. (NYSE:DPLO) was $0.24. This projection was computed after accounting 8 calls. As reported on 2016-05-09 the EPS was $0.23. The change was $0.05, demonstrating a percentage deviation of 27.78%. The projections confirmed a standard deviation of 0.03.
Quarterly Sales Estimates
For the fiscal 2017, the yearly sales target for Diplomat Pharmacy, Inc. (NYSE:DPLO) stands at $1624.985 and the median estimate at $1624.985. Almost 2 analysts announced their estimates.
The highest estimate is $1637.23 while the lowest target is $1612.74 showing standard deviation of 17.317%.
As many as 2 analysts released sales estimates reised in upside while 2 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 2 revised sales number projection on upside while 2 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 2 hiked sales estimations and 2 reduced sales forecast. Diplomat Pharmacy, Inc. (NYSE:DPLO) stated that the change in forecast was 11.138%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...